INZY

Insider Trades

Name	Value	Action	Price	Current Price
Treco Douglas ADirector, Officer: CEO & Chairman $7.8k8.8k shares SellApr 2, 2025 $0.89 --

Trade INZY

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

CEO: Douglas A. Treco
IPO Date: Jul 24, 2020

Market Data

Open: $4.00
High: $4.00
Low: $4.00
Volume: 1.5M
52W High: $6.24
52W Low: $0.721

Valuation

Market Cap: $258M
Enterprise Value: $279M

Financials

Free Cash Flow: $-92M
Revenue: $0
Net Income: $-102M
Cash: $21M
Debt: $47M

Events

EarningsAug 5

EPS est. -0.36 · actual -0.44